EE230 Clinical and Economic Outcomes Associated With Use of Anti-Arrhythmic Drugs Versus Ablation in Atrial Fibrillation (AFib)

Autor: Ken-Opurum, J, Vadagam, P, Faith, L, Srinivas, SSS, Preblick, R, Park, S, Charland, S, Revel, A

Publikováno v: In Value in Health December 2022 25(12) Supplement:S98-S98

Analyzing the Iatrogenic Triad: Discovering Strategies for Preventing Harm in the Elderly.

Autor: Mugada V; Vignan Institute of Pharmaceutical Technology, Department of Pharmacy Practice, Duvvada, India., Yarguntla SR; Vignan Institute of Pharmaceutical Technology, Department of Pharmaceutics, Duvvada, India., Allada SSS; Vignan Institute of Pharmaceutical Technology, Department of Pharmacy Practice, Duvvada, India., Paravastu KK; Vignan Institute of Pharmaceutical Technology, Department of Pharmaceutics, Duvvada, India., Puvvada SM; Vignan Institute of Pharmaceutical Technology, Department of Pharmacy Practice, Duvvada, India.

Publikováno v: Turkish journal of pharmaceutical sciences [Turk J Pharm Sci] 2024 May 14; Vol. 21 (2), pp. 159-166.

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.

Autor: Chauhan A; Axtria Inc., Berkeley Heights, NJ, USA. ankita.chauhan@axtria.com., Samnaliev M; Axtria Inc., Berkeley Heights, NJ, USA., Ken-Opurum J; Axtria Inc., Berkeley Heights, NJ, USA., Srinivas SSS; Axtria India Pvt. Ltd., Gurgaon, India., Mehta AM; Axtria Inc., Berkeley Heights, NJ, USA., Dex T; Sanofi, Bridgewater, NJ, USA., Charland S; Sanofi US, Golden, CO, USA., Revel A; Sanofi, Bridgewater, NJ, USA., Preblick R; Sanofi, Bridgewater, NJ, USA.

Publikováno v: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2023 Aug; Vol. 14 (8), pp. 1331-1344. Date of Electronic Publication: 2023 Jun 08.